AbbVie would gain an experimental eczema drug by buying biotech: report
AbbVie is reportedly trying to buy a biotech company that is developing a promising atopic dermatitis drug for $10.9 billion in cash, according to a Financial Times report.
Original Source
Read the full article at Marketwatch →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.